March 17, 2023

Andrew Norris - Co-Founder - BCN Biosciences

In this interview of Life Science Success my guest is Andrew Norris. Andrew is the co-founder of BCN Biosciences, a recent startup that has projects ongoing in the oncology drug space.

Show Notes
Guest Profile

In this interview of Life Science Success my guest is Andrew Norris. Andrew is the co-founder of BCN Biosciences, a recent startup that has projects ongoing in the oncology drug space.

Introduction

00:59 Tell listeners a little bit about yourself.

03:58 Can you tell us, just a little bit more about what it is that you're doing at UCLA today? And then also in Midvale Group?

09:03 What stage is BCN Biosciences currently in?

13:35 Do you still envision that this would be something that would be given to people that receive a high dose of radiation for some reason? Or is it, just in general?

21:02 What are some of the biggest challenges that you're facing at BCN?

27:06 So where do you see the biggest opportunities at BCN?

32:29 There are three questions that I like to ask every guest.

-What Inspires you?

36:11 -What concerns you?

41:16 -What excites you?

Please check out our Life Science Success Resources. You will find tools that will support growing companies and books for authors I have interviewed.

Andrew J Norris

President and CSO

Dr. Andrew Norris is Co-Founder, president and CSO of BCN Biosciences, a privately held pharma company in Pasadena CA. Dr. Norris has a varied background in both business and the technology sector. Dr. Norris co-founded BCN Biosciences, with the aim of creating novel approaches to the development of therapeutics in oncology and supportive care. Currently he oversees all research at BCN Biosciences and holds a research faculty position at The University of California, Los Angeles Semel Institute for Neuroscience and Human Behavior. He has also served as a consultant to many life sciences and healthcare companies. Dr. Norris technical background is formally in pharmacology and biochemistry with an emphasis in synthetic chemistry. He has worked with a variety of disciplines spanning across executive level business teams to chemistry, virology, immunology, oncology, and the process of drug developments. He has lead programs in the development of countermeasures for radiation toxicity for more than 10 years in collaboration with NIH, University of California, and Kansas University Medical center. He has also held key roles in work with the United States government Biomedical Advanced Research and Development Authority (BARDA) and has coordinated the activity of multiple centers (UCLA, CitoxLab North America (now Charles Rivers Laboratories, Cambridge Major Laboratories (now Alcami Corporation etc.), as well as served as the PI multiple contracts and grants with the National Cancer Institute, the National institutes of Allergy and Infectious Diseases (NIAID) among othe… Read More